NewAmsterdam Pharma Co N.V (NAMS) EPS (Weighted Average and Diluted): 2023-2025
Historic EPS (Weighted Average and Diluted) for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$0.61.
- NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) fell 238.89% to -$0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.05, marking a year-over-year increase of 8.89%. This contributed to the annual value of -$2.56 for FY2024, which is 19.07% down from last year.
- As of Q3 2025, NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) stood at -$0.61, which was down 306.67% from -$0.15 recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) ranged from a high of -$0.15 in Q2 2025 and a low of -$1.06 during Q1 2024.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.53, with a median of -$0.51 in 2023.
- Per our database at Business Quant, NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) spiked by 68.42% in 2024 and then slumped by 238.89% in 2025.
- NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.60 in 2023, then slumped by 58.33% to -$0.95 in 2024, then plummeted by 238.89% to -$0.61 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.61 for Q3 2025, versus -$0.15 for Q2 2025 and -$0.34 for Q1 2025.